seocalcitol
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 1999 (NCT00051532)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vitamin D receptorAGONIST
VDR agonist
Ph3 trials terminated, unknown reason
Chemistry & pharmacology
Loading structure…
SMILES
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O- Mol. weight
- 454.7 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1908376 ↗
Also known as
- 1(s),3(r)-dihydroxy-20(r)-(5'-ethyl-5'-hydroxyhepta-1'(e),3'(e)-dien-1'-yl)-9,10-secopregna-5(z),7(e),10(19)-triene
- 22-24-diene-24a,26a,27a,trihomo-1alpha,25-dihydroxyvitamin d3
- 22-24-diene-24a,26a,27a,trihomo-1alpha,25-dihydroxyvitamin d3
- (5z,7e,22e,24e)-(1s,3r)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,25-triol
- (5z,7e,22e,24e)-(1s,3r)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,25-triol
- cb-1089
- cb-1089
- eb1089
- eb 1089
- eb-1089
- eb-1089
- eb-1089
- seocalcitol
- seocalcitol
- seocalcitol
- seocalcitol
- seocalcitol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00051545 | Phase 3 | Nov 1, 1999 | Leo Pharma |
| NCT00051532 | N/A | Sep 1, 1999 | Leo Pharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Leo Pharma | For profit | 2 | 2 | 2 | 1999 |
1 organizations
Page 1 / 1